TELESIS BIO (TBIO)
(Delayed Data from NSDQ)
$3.09 USD
+0.16 (5.46%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $3.16 +0.07 (2.27%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
TBIO 3.09 +0.16(5.46%)
Will TBIO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TBIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TBIO
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Misses Revenue Estimates
TBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Telesis Bio (TBIO) Reports Q1 Loss, Misses Revenue Estimates
Emergent Biosolutions (EBS) Reports Q1 Loss, Tops Revenue Estimates
Beat the Market the Zacks Way: Hershey's, Telesis Bio, General Mills in Focus
Other News for TBIO
Biotech Alert: Searches spiking for these stocks today
Morning Movers: Designer Brands sinks following quarterly results
Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market
Telesis Bio to delist shares from Nasdaq
Telesis Bio to delist its securities from Nasdaq